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Abstract A case-mix project started in the Netherlands
with the primary goal to deﬁne a complete set of health
care products for hospitals. The deﬁnition of the product
structure was completed 4 years later. The results are
currently being used for billing purposes. This paper
focuses on the methodology and techniques that were
developed and applied in order to deﬁne the casemix
product structure. The central research question was how to
develop a manageable product structure, i.e., a limited set
of hospital products, with acceptable cost homogeneity.
For this purpose, a data warehouse with approximately 1.5
million patient records from 27 hospitals was build up over
a period of 3 years. The data associated with each patient
consist of a large number of a priori independent parame-
ters describing the resource utilization in different stages of
the treatment process, e.g., activities in the operating the-
atre, the lab and the radiology department. Because of the
complexity of the database, it was necessary to apply
advanced data analysis techniques. The full analyses pro-
cess that starts from the database and ends up with a
product deﬁnition consists of four basic analyses steps.
Each of these steps has revealed interesting insights. This
paper describes each step in some detail and presents the
major results of each step. The result consists of 687
product groups for 24 medical specialties used for billing
purposes.
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Introduction
The basic idea
The basic goal of this research is to establish a transparent
ﬁnancing system for health care in the Netherlands. The
core elements of the system are the diagnosis treatment
combinations (DBCs
1). The DBCs will be used as the basis
for remuneration negotiations between hospitals and
insurers. The focus of this paper is on the mathematical and
statistical methodology but the relevance of the results is
primarily in the health economics area.
In the DBC system, each DBC corresponds to a speciﬁc
problem with a speciﬁc treatment in a speciﬁc medical
discipline. A DBC represents a sequence of medical
activities that are performed during the treatment of a
patient. Hence, a DBC describes a complete care episode
rather than a speciﬁc instance of care (e.g., a single
activity). In most cases, a DBC starts already in an out-
patient situation and generally ends when the patient is
discharged from the hospital. Costs are allocated to the
intermediate products, i.e., the activities, the sum of which
gives the total cost of a DBC.
After ending the treatment, a DBC is a labelled data ﬁle
describing the whole care process in terms of activities.
The label, i.e., the DBC code, is a classiﬁcation code given
to the DBC by the medical specialist. The code reﬂects the
essential characteristics of the DBC and consists of three
attributes, namely 1. the diagnosis, 2. the treatment type
(ambulatory or clinical, conservative, or surgical) and 3.
the type of care (acute care, regular care and follow-up
treatment). Hence, a DBC code can be viewed as a sum-
mary or an abstraction of what is inside the DBC data ﬁle
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the system depends strongly on how accurate the DBC
codes are in this respect: Each patient and each treatment is
unique but there are only a limited number of codes and a
corresponding limited number of billable prices. Essen-
tially, this paper is about the development of an accurate
classiﬁcation system for ﬁnancing health care.
The DBC project started at the beginning of 2001. At
that time, a project organization, funded by the Dutch
Ministry of Health care, started with organizing the
implementation of DBC registration in 27 Dutch hospitals.
This team was formally controlled by a steering committee
in which all relevant parties (ministry, medical specialists,
hospital management and health care insurers) were
represented.
A glossary of the DBC product structure
The DBC product structure has two levels. The ﬁrst level is
highly detailed and consists of the individual DBC codes.
A DBC code consists of three components each charac-
terizing different aspects of the care episode, namely the
care type (‘regular care’, ‘emergency consult’, ‘second
opinion’, etc.), the diagnosis and the treatment (which
includes aspects such as ‘surgical activities’, ‘conservative
treatment’, ‘day-care treatment’, ‘treatment including
nursing days’, etc). This level of detail was considered
necessary to give medical specialists the freedom to char-
acterize individual DBCs. The characterization has to be
precise in order to give an accurate estimation of the
treatment and its associated costs and, more importantly, to
compare DBCs within hospitals and between hospitals. As
a consequence, there are many different possible codes
(all possible combinations of the three components). More
than 20,000 different DBC codes where registered in the 27
hospitals, and there are more than half a million theoreti-
cally possible codes. The second level deﬁnes the actual
products that are used for the purposes of negotiation,
yearly budgeting and billing. Each health care product
deﬁned in the second level corresponds to a group of DBC
codes from the ﬁrst level. Together the set of products in
the second level is complete, i.e., each ﬁrst level DBC code
is member of a second level product. This paper focuses on
the development of the product group level.
There is a long tradition in the development of casemix
systems for health care.
2 In the late seventies, Fetter et al.
[1] from Yale University developed a new casemix system
in the Unites States for hospital funding. This casemix
system is nowadays known as the DRG (diagnosis-related
groups) system. Many variants of the DRG system, for
example Nord-drg (Sweden, Norway, Denmark), HCFA
drg (United States), Ar-drg (Australia), are nowadays
(partly) used for the reimbursement of hospitals. The Dutch
endeavour is a similar development towards casemix-based
funding. Welvaarts et al. [2] describe the reasons for
developing a new casemix system and give an overview of
the differences between the two systems.
For the development of a DBC grouping methodology,
the following items are speciﬁc for the Dutch situation.
1. The physicians are for the larger part independent and
not as employees’ part of the different hospitals
organizations. One of the consequences is that the
medical professions were made responsible for deﬁn-
ing their own DBC classiﬁcation system. The results of
this are as follows.
a. Medical specialists working in a given medical
specialty are organized in the scientiﬁc organiza-
tion for that specialty. Each scientiﬁc organization
independently developed its own diagnosis classi-
ﬁcation system. These systems cannot be related to
the ICD classiﬁcation.
b. In addition to the diagnosis, other components
were also thought necessary for characterizing a
DBC, i.e., ‘Type of Care’ and in some specialties
the ‘Complaint of the Patient’.
c. The diagnosis classiﬁcation systems do not have a
hierarchical structure as in ICD systems. Hence,
only one detailed description level was available
so that diagnosis could not be clustered together
based on medical similarities as is done in DRG
systems.
d. Products had to be developed independently per
specialty.
e. The specialist should be able to specify the DBC
code manually. In DRG systems, there is no such
constraint and the code can be derived using a
more complex algorithm. In the DBC systems,
algorithms are used afterwards to check the
consistency of the treatment classiﬁcation with
the DBC ﬁle.
2. Registration of medical activities in hospitals is done
using the Dutch CTG classiﬁcation system. This is a
classiﬁcation of medical activities originating from the
Dutch Tariffs Organization in Healthcare.
3. Not only the total cost and length of stay of an
individual DBCs was available but also the cost of
each individual medical activity. The sum of these
individual costs is the total cost price of a DBC.
4. The full episode from outpatient visit until discharge is
part of the DBC including all outpatient care, day care
and mixed care (partly outpatient and partly clinical).
2 See for example, the yearly PCSE (patient classiﬁcation systems
europe) conferences and their proceedings.
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1235. There is a data set available (representing 1.5 million
patients treated in 27 hospitals during 3 years).
All these points have consequences for the manner in
which the DBC products can be formed. From a method-
ological point of view, some points can be regarded as a
disadvantage (no hierarchical diagnoses information,
forced simplicity of treatment type) and others as an
advantage (detailed activity/procedure information, full
episodes and cost data of medical activities). The meth-
odology used to deﬁne DBC groups which is presented in
this paper is aimed to be optimal in the light of the situation
described above and in the light of the criteria of classiﬁ-
cation accuracy (cost homogeneity) and manageability
(limited number of products and medically homogeneous).
The institutional economic context
The public policy is to translate former social goals into
products (Diagnosis-Related Groups, DRGs) with product
prices [3, 4]. Also in the Netherlands, changes are being
introduced in the health care legislation, and a regulated
market competition is being introduced for hospitals [5].
The new reimbursement system for hospitals in the Neth-
erlands is an episode-based fee for service system. By
introducing this, the speciﬁc diagnosis of the patient
becomes the focus of the calculation [6]. The DBC product
structure has a number of important differences compared
with the DRG product structure. First, in the DBC casemix
system, the doctor opens and closes diagnosis treatment
episodes. The resulting episodes consist of diagnoses and
treatment information, and the intermediate products,
which can be analysed in terms of costs, time and quality.
Secondly, DBC cost prices are not calculated by using cost
weights as is the case in DRG casemix systems (e.g., [7]).
Cost prices of DBCs are calculated using a cost allocation
system that results in cost prices for intermediate products.
The sum of intermediate products in a DBC episode leads
to the DBC cost price. Doing so, the homogeneity of DBC
cost prices can be determined. Inhomogeneity leads to
ﬁnancial risks for hospitals (see [8]). Thirdly, in the DBC
casemix reimbursement system, episodes are opened
whenever there is a new demand for care. This implies that
for one patient, parallel DBCs can exist and can be billed.
A more extensive overview of differences between case-
mix reimbursement systems can be found in [4].
Whereas the former reimbursement system distin-
guished between private insurances and the Dutch National
Health Service, the new system only offers room for a basic
private insurance with extra insurance options, e.g., dentist
costs. In the new system, the key element is competition
and the goal is to improve quality of care and reduce costs.
With the deregulation of the health care market, three
markets emerged: the insurance market, the health care
market and the care purchase market. Three major actors
can be distinguished: the patient/consumers, the insurers
and the health care providers. Furthermore, there are the
regulatory authorities [(e.g., The Dutch Health Authority
(NZa) and the Netherlands Competition Authority (NMa)].
Although competition is a key element, the health care
market is closely watched by the authorities to guarantee
quality and accessibility of health care. One of the inﬂu-
ences of the authorities besides quality legislation is pric-
ing. Nowadays, still 70% of the pricing is done by the NZa,
whereas the remaining 30% is negotiated between insurer
and health care provider. This 30% is called the B-segment
which is basically a free hospital market where price,
quality and volume are due to negotiations between hos-
pitals and insurers. This increases the ﬁnancial risks for
hospitals as well as insurers. Two important notions about
competition in health care must be considered; ﬁrst, the
process of supply and demand is different from most
markets, because it is indirect through a third party: the
health insurers. The second notion is that in case of hos-
pitals, their competitive position determines what products
it can and will offer, because hospitals must in addition to
market share also compete for professional expertise [9].
Professional expertise is reﬂected in the experience gained
from the treatment of diseases or the repetition of surgical
procedures. This experience can only be gained when a
hospital has enough market share. Although the average
costs of the casemix can be reimbursed, some hospitals
may still face substantial ﬁnancial risks [8]. Some hospitals
have higher costs, due to their casemix, due to patient
characteristics, or due to inefﬁciency. Lynk [10] presents a
comprehensive overview of problems which causes ﬁnan-
cial risks for hospitals. Because of intra DRG differences,
cost differences across patients within the same hospital or
between hospitals, hospitals could be underpaid or over-
paid. Lynk [10] argues that ‘‘…the concern that the system
disadvantages certain types of hospitals relative to other
types of hospitals is real, not hypothetical’’ [10]. Eldenburg
and Kallapur [11] show that hospitals respond to these
ﬁnancial risks by changing their patient mix and internal
cost allocations to maximize hospital net cash ﬂows. There
are three generic strategies to realize this.
• Cost leadership (lowest costs per unit).
• Segmentation (dividing the market in different seg-
ments, like acute care, complex care, non-complex
care, diagnostics and chronic care).
• Specialization (produce a unique product by special-
ization, like heart surgery, HIV treatment, or invasive
surgery).
These strategies can be applied independently but some
hospitals seek collaboration with other hospitals to enhance
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123their competitive position in a region. Key element of the
new Dutch health care system is competition. This new
phenomenon is issued by deregulation of the Dutch hos-
pital market. An issue when going from a regulated envi-
ronment to a deregulated environment is that there is no
historical evolution and that all participants have little
understanding of how it will operate in the short term and
evolve in the future. Some hospitals therefore seek col-
laboration. Collaboration is mostly associated with lower
costs due to economy of scale The research focused on
collaboration of hospitals shows that ﬁnancial beneﬁts are
probably not likely [12].
Realizing a product structure that is accepted widely by
all parties cannot be merely statistical exercise. For
example, bringing in medical input which cannot be
operationalized in a quantitative manner is crucial for
acceptance by the medical community. In our approach, we
included the medical input in a systematic way. Each
speciality, for example urology and internal medicine, is
represented by a formal scientiﬁc committee with experi-
enced medical specialists. After ﬁrst grouping the DBCs
using statistical data analyses, the scientiﬁc committees
reﬁned the clustering based on their medical judgment.
These expert sessions with the specialists were facilitated
by statistical expert to govern the statistical relevance of
the end result. This paper focuses on the ﬁrst step, i.e., to
deﬁne a statistically sound product structure from hospital
data.
The paper is organized as follows: Sect. 2 gives an
overview of the available DBC data and the cost
accounting methodology. Section 3 presents the product
deﬁnition methodology and its results. The method consists
of three analysis steps that are described separately in the
Subsect. 3.1 (criteria for the DBC product structure), 3.2
(overview of the analysis process) and ﬁnally Subsects.
3.3 (identifying clinical pathways), 3.4 (determining the
relation between clinical pathways and the DBC codes) and
3.5 (deﬁning product groups). Section 4 discusses the
results of this casemix research project.
The registration level and the DBC database
This section describes the DBC data that are registered in
Dutch hospitals. It also gives an overview of the volumes
of data that were available for deﬁning the DBC product
structure.
The DBC data set of a single patient
Table 1 gives four examples of DBC codes. A DBC code is
registered by the physician for each episode of care (from
intake until discharge) for each patient. The ﬁrst position of
the code is an indicator of the specialty, the second position
represents the care type, the third position is the diagnosis
and the ﬁnal position represents the treatment type. For
each component within each specialty, there is a list of
codes that are used by the physicians to characterize their
DBCs, i.e., episodes of care.
The activities that have been performed for the DBC are
registered separately by the administrative departments.
Each activity is labelled with a code (a CTG
3 code) that
classiﬁes what has been done. Each code belongs to an
activity class. An example of a DBC activity data ﬁle is
given in Table 2. In total, there are 3,030 different CTG
codes for medical activities.
Together the DBC code and the DBC activities form the
DBC data ﬁle. There is also additional information
Table 1 Examples of DBC codes
DBC code Speciality
code
Care type
code
Diagnosis
code
Treatment
code
Specialty Care
type
Diagnosis Treatment
1.11.654.33 1 11 654 33 Eye surgery Regular
care
Retina defect/retina
peel off
Procedures with clin.
episodes
3.11.323.303 3 11 323 303 General surgery Regular
care
Cholecystitis/
cholelithiasis
Surgery-endotechnical
with clinical episodes
5.11.3019.213 5 11 3,019 213 Orthopaedic
surgery
Regular
care
Femur proximal
(?collum)
Procedures with clin.
episodes
30.11.201.113 30 11 201 113 Neurology Regular
care
Neopl. Intracerebral Regular treatment with
clinical episodes
5.11.1450.111 5 11 1,450 111 Orthopaedic
surgery
Regular
care
Tendinitis
supraspinatus/
biceps, cq.
impingement
Conservative
ambulatory
For each patient, a DBC code is assigned to characterize the diagnosis and the treatment of the patient
3 College Tarieven Gezondheidszorg: The Dutch Healthcare Tariffs
Organization.
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123associated to the data ﬁle such as the patient ID, patient age
and gender.
The DBC database collected from the pilot hospitals
Table 3 gives an overview of the total number of DBC
codes that were available in the central data warehouse and
suitable for analyses at January 2004.
4 For reasons of sta-
tistical signiﬁcance, we needed a sufﬁcient number of
observations (counted in numbers of individual patients)
per DBC code. DBC codes that were registered less than 5
times were left out from further analyses. As can be seen
from Table 3, the effect of leaving out these codes has a
large effect on the number of distinct DBC codes. Figure 1
shows the cumulative distribution of DBCs over the DBC
codes in General Surgery.
InFig. 1,1,200distinctcodesaresortedfromlargetosmall
according to the number of DBCs that were registered with
each code. Approximately 150 codes (12.5%) are responsible
for 80% of all DBC registrations in General Surgery. Same
patterns are found for other medical specialities.
Calculating cost prices of medical activities
In this paragraph, we give a short description of the
methodology which was used to calculate a unique cost
price for each medical activity as classiﬁed by the CTG
classiﬁcation in each hospital (for example € 50 for the
1st outpatient visit). Cost accounting in Dutch hospitals is
not a widespread phenomenon, because of the budgeting
system hospitals are faced with. However, there are a
number of examples of hospital cost accounting meth-
odologies known, see e.g., Eldenburg and Kallapur [13],
Reed et al. [14], Lynk [10], Younis et al. [15] and Ross
[16]. Before choosing a cost accounting methodology, a
few important guidelines were deﬁned by the national
steering committee.
First, the cost accounting model should be based on cur-
rent approaches and techniques. Secondly, the model should
not introduce new registrations. It should only be based on
current registrations within the hospital. Thirdly, the costing
model should be easy to use and maintain. Fourthly, the
model should imply all hospital costs. Fifthly, the costing
model should use the costs and production as registered in a
given period. As a result, possible inefﬁciency is incorpo-
rated in the model. The resulting cost accounting method-
ology(seeFig. 2)isaproductioncentreapproachwithdirect,
step-down or reciprocal allocation of indirect hospital costs
to the costing objects: medical activities (intermediate
products) as classiﬁed by the CTG classiﬁcation.
We are interested in the homogeneity of the care
proﬁle of a group of DBCs in a product. We are not
interested here in differences between hospitals in the
manner in which they account costs to a given activity.
For example, the costs of a haemoglobin test in hospital
A could be 25% higher than in hospital B. In terms of
care that is provided, however, the activities are identical.
For this reason, we calculate a median cost price for each
type of activity, based on the individual cost price for
each activity as calculated by every participating hospital.
The median cost prices of these activities or intermediate
products were used to determine the cost homogeneity of
the resulting DBC care proﬁle.
Table 2 Example of the activities that were performed for a patient with DBC code 1.11.654.33 (eye surgery, regular care, retina defect/retina
peel off and surgery with clin. episodes)
CTG code Description Activity class Description Number of activities Total costs
190011 ﬁrst outpatient visit 1 Ambulatory care 1 € 50.00
2 Day care € –
190204 Nursing day class 3a 3 Nursing days 2 € 572.00
4 Diagnostics € –
31294 Vitrectomy 5 Surgical procedures 1 € 470.00
31348 Treatment Ablatio Retinae 5 Surgical procedures 1 € 809.00
6 Additional medical procedures € –
7 Radiology € –
8 Laboratory diagnostics € –
12 Paramedic aids € –
13 Special artiﬁcial parts € –
€ 1,901.00
4 The DBC data obtained from the hospitals went through data pre-
processing activities and error correcting ﬁlters (consistency checks,
check against registration guidelines, outlier ﬁltering). This process is
too complex to meaningfully describe for the purposes of this paper.
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123From hospital data to a DBC product structure:
methods and results
Criteria for the DBC product structure
The research object in the development of the casemix
system is the grouping of all possible DBC codes in a
manageable number of billable products. Whereas for
medical management purposes a detailed description of the
‘‘clinical’’ pathway (both inpatient and outpatient) is nee-
ded, for management control purposes and for reimburse-
ment purposes the detailed number of DBC codes should
be grouped in a manageable product structure. This product
structure can be used in negotiations between hospitals and
health care insurance companies. The large numbers of
DBC codes are not necessary for allocating budgets and for
controlling costs. The research objective therefore was to
Table 3 Overview of the total numbers of DBCs and DBC codes in the central data warehouse suitable for data analysis
Medical
specialty
# DBC’s
in GDWH
# of unique DBC
codes in GDWH
# DBC’s excl. DBC’s
in DBC codes with less than
5 observations
# DBC codes excl. DBC
codes with less than
5 observations
Eye surgery 1,43,042 1,298 1,41,277 482
Dermatology 64,381 950 63,115 356
Internal medicine 1,10,752 2,809 1,06,905 778
Gastro enterology 26,596 508 26,228 279
Head and neck surgery 61,972 1,294 60,067 338
Cardiology 53,819 524 53,174 248
Rheumatology 20,894 351 20,432 144
Rehabilitation 10,023 1,297 8,496 372
General surgery 1,91,618 1,566 1,89,602 610
Neurology 80,960 1,028 79,976 480
Clinical geriatrics 2,048 423 1,584 99
Plastic surgery 13,059 804 12,155 211
Orthopaedic surgery 90,109 2,674 86,265 793
Urology 39,727 2,837 36,418 773
Gynaecology 82,773 764 81,786 281
Neurosurgery 5,775 281 5,330 68
Anaesthesiology 33,646 382 33,071 110
Paediatrics 37,633 3,702 25,790 985
Pneumonology 45,706 925 44,396 302
Sum 11,14,533 24,417 10,76,067 7,709
200 400 600 800 1000 1200
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20
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40
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Fig. 1 Cumulative distribution of DBCs over distinct DBC codes for
General surgery. The cumulative percentage is plotted along vertical
axis versus the number of codes on the horizontal axis
Costsof
support cost centers
Costsof 
Production centers
Costingobjects
(CTG-codes)
DBC(clusters)
Fig. 2 Cost accounting methodology
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123deﬁne a product structure that encompasses a small set of
products, with each billable product having a minimum
variance in costs.
The following criteria for the casemix product structure
were deﬁned.
• The number of products must be limited to about 600
products (20–40 per specialty).
• The products must be homogeneous from the point of
view of hospital resource utilization.
• The product structure is not meant to be a theoretical
construct, i.e., the product structure can only be
introduced if it is based on a sufﬁciently representative
and valid data set.
• The product structure can only be introduced if it is
statistically sound, i.e., if the choices that are made can
be well motivated statistically and conﬁdence estimates
can be given of the main statistical parameters in the
product set, average costs of products, cost variance,
etc.
• A less quantitative constraint is that the product
structure must be accepted by the ‘‘scientiﬁc commit-
tees of medical specialists’’. Doctors have to accept the
product structure as acceptable from a medical per-
spective. They must see the product structure as a
logical grouping of diseases. This condition was
fulﬁlled by consulting the scientiﬁc communities of
medical specialists about the results. Their input was
used to adapt and reﬁne the product structure.
Together with the speciﬁc constraints that were given in
the introduction, the method presented in this section is
aimed to provide an optimal balance between the criteria
above.
Overview of the analysis process resulting in product
group deﬁnitions
As described in the previous section, the central data
warehouse stores for each treatment of each patient a DBC
code together with all associated activity codes and their
costs. The basic idea is to identify common activity pat-
terns and their relation with DBC codes in this data set in
order to deﬁne a small set of homogeneous product groups.
Figure 3 gives an overview of the steps that were taken
to deﬁne product groups. It is important here to realize that
some of the ingredients of the methodology were given as
constraints deﬁned by policy. In short, these constraints
were as follows: (1) work with DBC codes, i.e., the DBC
code should be printed on each bill provided by the health
care provider to insurer and (2) group DBC codes into
homogeneous product groups with a ‘group-price’.
This means that the analysis process should basically
optimize the grouping of DBC codes. In addition, there is
some room to improve the treatment type, i.e., the fourth
component of the DBC code.
In the ﬁrst step of the analysis, we identify groups of
DBCs (each DBC is an episode of care of one patient) in
the hospital data having similar activity proﬁles. Here, we
only consider the activities and their costs and ignore the
DBC code, i.e., the diagnosis and treatment label given by
the medical specialist. Forming groups of DBCs is done
using statistical clustering methods, see Sect. 3.3. Each
resulting group deﬁnes a clinical pathway. In other words,
a clinical pathway is a group of similar care episodes.
Patients in a clinical pathway undergo similar activities in
their path from intake until discharge. By construction, the
groups are homogeneous in costs
5 and activities. As we
shall see later, for the purposes of forming a product
structure, the clinical pathways are only very helpful
intermediate products. Deﬁning clinical pathways from
patient activity data could however be very useful for other
purposes as well, especially for hospital management
where standardizing pathways can greatly improve quality
and efﬁciency.
Since each patient is both assigned to a clinical pathway
and has a DBC code label, we are able to analyse the
relation between DBC codes and clinical pathways. By
doing this, we are able to identify the sources of
Step 1:  
Identify clinical
pathways
Step 2:  
Determine relation
Between DBC  
codes and 
clinical pathways 
Step 3:  
Determine 
product groups
Central 
Datawarehouse
(CGAO)
DBC product structure
: 
Hospitalregistration
Activities and costs
Refine DBC 
Treatment type
DBC codes
Fig. 3 Schematic overview of the methodology. DBC codes, activ-
ities and costs are provided by hospitals. The corresponding coding
tables and costing methodology used by hospitals to register these
data were deﬁned by policy. The methodology presented here
encompasses steps 1 thru 3 and is focussed on forming groups of
DBC codes based on the information available from activities and
costs
5 Note that we use a unique cost price per activity code, namely the
median cost price over the hospitals (see Sect. 2.3). Differences in
costs between two treatments are therefore caused by differences in
which activities are performed, the number of activities and their
median cost price.
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DBCs with very distinct clinical pathways, e.g., a clinical
path and an outpatient path, being associated to the same
DBC code. Using this insight, we are able to reﬁne and
improve (in the example, we would introduce different
codes for clinical and outpatient DBCs) the DBC code list
so that each code relates to a small group of similar clinical
pathways. After having optimized the DBC code list, we
group all possible DBC codes into a small set of product
groups. Again, we use the clinical pathways to deﬁne a
measure of similarity between the codes. The groups are
formed by using a clustering algorithm. Finally, the groups
are reﬁned manually. Here, other considerations (policy,
management and politics) besides statistics, costs and
treatment properties come into play, i.e., those factors that
are hard to implement algorithmically. We treat this as a
separate ﬁnal step in the deﬁnition process, see Sect. 3.5.
Step 1: Identifying clinical pathways
We use a two-step approach to identify clinical pathways:
First, we identify clusters of DBCs with a similar activity
proﬁle within a given activity class (as deﬁned in Sect. 2.1).
Each DBC is then reduced to a sequence of cluster labels,
one for each activity class. In the second step (global
clustering), we identify the clinical pathways by analysing
the similarities in these sequences. For example, two DBCs
that are in the same cluster in each activity class will also
be member of the same clinical pathway. Both steps are
described in the following two subsections.
Local clustering within activity classes
The objective of a clustering algorithm is to identify
homogeneous clusters of data points based on similarity of
the data points. Figure 4 shows the laboratory activities of
a care episode of one patient. Figure 5 shows the activity
proﬁles of a large number of DBCs. Comparing all activity
proﬁles of all DBCs in this way, it is immediately clear that
there is a lot of variation and that it is practically impos-
sible to ﬁnd clusters of DBCs by hand.
Before the automatic cluster procedure can start, we ﬁrst
need to deﬁne how the similarity between two activity
proﬁles of two patients is determined. Standard measures
for determining distance (roughly the inverse of similarity)
in clustering algorithms are the Euclidian distance and the
inner product or Cosine distances. One important criterion
for selecting a measure is its effect on forming clusters.
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Fig. 4 Visual representation of
the activity sequence of a DBC
for one patient in one activity
class (laboratory). All
laboratory activity codes are
placed on top of each other in
ﬁxed order. The black and white
indicators visualize which
activities were registered and
which were not for the patient
All patients in the lab
Fig. 5 Laboratory activity proﬁles of 2,000 DBCs. The DBC activity proﬁles of Fig. 5 are placed next to each other. The CTG activity codes are
ordered vertically where the most frequent activity is positioned on top (this is why the dark to light pattern goes from top to bottom)
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123Measures that do not qualify are those which give unstable
clustering results, i.e., quickly and at random forming a few
very large clusters and a lot of very small clusters. For
similar applications, it was found that the ‘Jaccard’ simi-
larity measure
6 performs best [17]. Roughly, this measure
is in between the Euclidian and the inner product measure,
i.e., counting the number of common activities. The fact
that it works makes sense: two points can be very close in a
Euclidian sense and not share any common dimension (a
point on the x-axis can be close to the y-axis). This would
be strange if we would compare care episodes. The inner
product adds weight to the fact that two episodes share the
same activities. Also in comparative clustering experiments
with DBC data, it was found that the Jaccard measure
resulted in very well-balanced clusters. Besides activities,
we also take into account total costs of two episodes. If two
episodes have no activities in common, they can still be
similar if their costs are similar. The amount of weight that
is given to this ‘cost-dimension’ can be adjusted by
changing a single cost-weight parameter.
After computing the similarity between each pair of
proﬁles, we are able to form clusters. For this, we use an
‘agglomerative clustering algorithm’ [17]. The basic idea is
that at each step, the two activity proﬁles that are most
similar to each other are merged into one cluster. In the next
step, this cluster is treated as one single proﬁle. Clusters and
sequences are merged together until at some point the
clustering is optimal. Here, we take into account our
objectives of proﬁle homogeneity, cost homogeneity and
number of clusters.
The result of clustering the episodes in Fig. 5 is shown
in Fig. 6. DBCs (or care episodes) that are member of the
same cluster are displayed adjacent to each other. The thin
vertical lines indicate the boundaries of a cluster. We
clearly see a pattern of horizontal bars which characterizes
the activity proﬁle of each cluster: Each emerging hori-
zontal bar/line corresponds to the common presence of a
speciﬁc CTG activity in a cluster. Besides the common
patterns, we see a lot of noise.
Global clustering for identifying clinical pathways
The sequence of activities performed for each DBC can
now be represented by a sequence of cluster labels within
each activity class. An example of such a sequence for one
single DBC is given in Table 4.
Table 5 shows some examples together in one table
(each row here corresponds to one DBC episode). The table
20 clusters
Fig. 6 Same activity proﬁles as in Fig. 5 but now ordered by our
clustering algorithm. The vertical lines indicate the boundaries of the
clusters. The result visualizes the 20 clusters of activity proﬁles for
laboratory activities in Urology. Each Urology DBC in the data
warehouse is member of one of these 20 clusters. A similar result is
found for all the other activity classes (surgery, diagnostics, etc)
Table 4 Representation of a
single patient speciﬁc DBC care
episode
Activity class Description Total costs Cluster ID per
activity class
1 Ambulatory care € 182.00 2
2 Day care € 0.00 0
3 Nursing days € 3,817.00 3
4 Diagnostics € 0.00 0
5 Surgical procedures € 1,413.00 6
6 Additional medical procedures € 0.00 0
7 Radiology € 107.00 1
8 Laboratory diagnostics € 153.00 2
12 Paramedic aids € 0.00 0
13 Special artiﬁcial parts € 0.00 0
6 More precisely, the Jaccard similarity between two vectors x ~and z ~
is deﬁned as Jz ~; x ~ ðÞ ¼ z ~  x ~= z ~  x ~þ z ~  x ~ kk
2

. For DBCs a vector
would represent its activity sequence, e.g. if there where N distinct
activities x ~¼ 1;1;0;0;...;0;1 ðÞ would represent a DBC for which
activity 1, 2 and N where performed. Instead of a binary (yes/no)
representation, we can also represent the number of times the same
activity was performed or the costs involved with the activity.
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123shows only a small fraction of all the combinations that are
observed. Clearly, a further reduction of complexity is
necessary to get a manageable number of clinical path-
ways. This is the objective of the global clustering, the
result of which gives the clinical pathways that each
describe the average activity sequence of a group of DBCs
from intake to discharge.
In order to reveal the similarities between the DBC epi-
sodesasinTable 5,wesummarizethesetofallepisodesina
decision tree such as in Fig. 7 for Neurology. The top node
segments all 72,851 DBCs based on their cluster ID in the
class of for the ‘surgical procedures’ (oper). Depending on
the outcome, each resulting subset is again segmented
according to one of the remaining activity classes.
The segmentation continues until we reach a leaf in the
tree. Alls DBCs that end up in the same leaf are very
similar to each other in terms of their activity proﬁle within
different activity classes.
The tree is constructed using a decision tree algorithm.
7
In short, this works as follows: at each node, the activity
class is chosen such that the resulting segmentation of the
episodes is maximally homogeneous in costs.
8 Each
Table 5 Representation of a 8 DBCs in terms of (local) clusters in activity classes
DBC episode # Ambulant Day care Clinical Diag Oper Therap Radio Lab diag Para Special
11132 1 0 0 0 0 0 0 0 0 0
11817 1 0 0 0 2 0 0 1 0 0
5824 1 0 3 0 4 0 0 0 1 0
7025 2 0 0 0 0 0 0 1 0 0
56905 1 0 0 0 0 0 0 0 0 0
33620 2 0 1 0 0 2 1 0 0 0
44153 1 0 0 0 0 0 2 0 0 0
77287 2 0 0 0 1 0 0 0 0 0
Cluster 0 always corresponds to the empty cluster with 0 Euro’s costs. In most medical specialties, there are over 2000 unique episodes in this
representation
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Fig. 7 Clinical pathways found for Neurology. The top node contains
all 72,851 patients. This group has a cost homogeneity of 2.24. The
group divided into 5 sub groups depending on the operating theatre
(=surgical activities) category. Each clinical pathway is formed by
following a branch from ‘root’ to ‘leaf’. Note: ‘therap’ = ‘additional
medical activities’, ‘clinical’ = ‘nursing days’
7 The (decision tree) algorithm that is used here is closely related to
well-known algorithms in statistics such as CART [18] and C4.5 [20].
8 More precisely, the criterion used here is ‘minimum weighted
average CV’, where the weight is given by the number of patients in
each branch.
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123resulting group is then segmented again in the same man-
ner. The segmentation continues 1) until the cost homo-
geneity cannot be sufﬁciently increased further
9 or 2) until
the resulting subsets become too small [18].
The tree shown in Fig. 7 deﬁnes clinical pathways for
Neurology. Thegoal of the algorithmisto ﬁnd agroupingof
the 72,851 Neurology episodes in the database. Remember
thatforeachactivityclass,wealreadyhavefoundclustersof
episodes. For Neurology, we found 5 clusters (0,1,…, 4) for
everything that is happening in the operating theatre. Here,
cluster label 0 means that nothing happened and label 4
represents the most complex group of episodes (many
expensive surgical activities per episode per patient).
The algorithm discovered that ‘operating theatre’
activities are most informative, i.e., if you know in which
‘oper’ cluster the episodes fall, then the cost inhomogeneity
of all costs (also the non-oper costs) is maximally reduced.
That is why ‘oper’ is in the top node for Neurology. For
each of the resulting groups, the algorithm does the same
trick. For example, for the node representing the group
with 62,122 episodes without any surgical activity, the
algorithm found that the ambulatory activities are most
discriminative in reducing cost inhomogeneity. We see that
the tree continuous to split up the group of episodes along
the left branch until it stops after splitting up according to
the laboratory diagnostic activities.
The deﬁnition of sufﬁcient homogeneity gain is a free
parameter with which we can control the amount of detail
in the tree. In general, there is a trade-off between amount
of detail, i.e., number of resulting clinical pathways and
average cost homogeneity in the clinical pathways. This is
shown in Fig. 8 where we plotted the number of clinical
pathways (equivalent to increasing the tree size) against the
average CV
10 of the episodes associated with each clinical
pathway. The optimal number of clinical pathways is
chosen such that if we increase this number we hardly
increase the cost homogeneity and if we decrease the
number of paths we get a strong decrease in the cost
homogeneity.
Result of step 1: Clinical pathways
As in the example for Neurology in Fig. 7, we performed a
local clustering and a global clustering, respectively, to
construct a decision tree for each medical specialty. The
resulting number of groups, i.e., clinical pathways that we
found for each medical specialty, is given in Table 6.O n
average, we found 67 clinical pathways per specialty where
each clinical pathway represents about 900 DBC codes.
In Sect. 3.3.1, we explained that in order to ﬁnd clusters
within activity classes, for example in the laboratory, we
can adjust the relative weight that is given to the total costs
of the activities. The CTG code system, that was used to
register activities on the most detailed level, was originally
designed as a cost declaration system. In the cluster anal-
ysis, we found that this coding is not suitable to compare
DBC proﬁles: In order to have a meaningful measure of
similarity between activity proﬁles of DBCs, we need to
quantify information about the similarity of individual
activities (from a medical point of view or from a care
management point of view). This information was not (yet)
available in the CTG system. Hence, for a meaningful local
clustering, it was necessary to put all the weight on costs.
This means, for example, that in the laboratory, we seg-
ment DBC proﬁles based on the sum of the costs that were
made for each DBC in the laboratory. The local clusters are
therefore equivalent to cost levels (see for example, the
cluster IDs in Table 4). The global clusters on the other
hand are still distinguished depending on where the costs
were made: a DBC with € 1,000 spent mainly in the lab-
oratory is member of a different clinical pathway than a
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0.25
0.3
0.35
0.4
0.45
0.5
0.55
0.6
0.65
0.7
# of care paths
a
v
e
r
a
g
e
 
c
o
s
t
 
i
n
h
o
m
o
g
e
n
e
i
t
y
Fig. 8 Average CV of each clinical pathway (=care path) versus the
number of clinical pathways
9 We do this by using a ‘pruning algorithm’, where we ﬁrst fully
develop the tree with all its detail and then prune those branches
which do not result in sufﬁcient decrease of the average CV value. To
be more precise, the homogeneity of the episodes in a node is
compared to the average homogeneity of all end nodes (leafs) of the
whole subtree under the node. If the sub-tree does not signiﬁcantly
increase homogeneity, the whole subtree is pruned. Here, we also take
into account the statistical uncertainty of the computed homogeneity
in each node.
10 Cost homogeneity is deﬁned using the coefﬁcient of variance
(CV), see for example Fischer [19]. The CV of the costs of a group of
patients is deﬁned as the standard deviation of the costs of in the
group divided by the average costs. The lower the CV, the higher the
cost homogeneity of the group. This measure of homogeneity has
been widely used in evaluating casemix systems (e.g. Fischer [19]). In
most research, a CV smaller than 1 is being accepted as reasonable.
Because this criterion is based on DRG systems, which only involve
clinical costs whereas this research uses clinical as well as outpatient
costs, we will not compare our results with this standard. Here, the
goal is simply to end up with an average CV as small as possible,
preferably smaller than 1.
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123DBC for which € 1,000 were spent in the theatre. This
choice to construct local clusters in each activity class
based on cost similarities only is suboptimal with respect to
the criterion of medical homogeneity. The medical homo-
geneity is now attained only from the global clustering
(two DBCs having the same total costs are still in different
clinical pathways if the costs were made in different
activity classes, say in day care vs. nursing days). Never-
theless, to increase medical homogeneity of clinical path-
ways in future versions, we need to incorporate additional
information with the CTG system so that we can perform a
more reﬁned clustering in each activity class.
From Table 6, we see that the average CV of clinical
pathways is about 0.45. The average CV of the original
DBC codes given by the medical specialist is 1.63 using
24,417 distinct codes! Hence, the clinical pathways seg-
ment the DBC data set into a smaller number of more
homogeneous groups.
Step 2: Determining the relation between clinical
pathways and the DBC codes and reﬁning treatment
type
After having identiﬁed the clinical pathways, each DBC in
the central data warehouse has two labels, a label corre-
sponding to the DBC code of the DBC and a clinical
pathway label. As discussed before, the DBC codes
segment the set of DBCs in a huge number of cost
inhomogeneous subsets of care episodes, whereas the care
paths segment the episodes in a small number of cost
homogeneous subsets. The relation between DBC code
labels and clinical pathway labels can be visualized as
shown in Fig. 9. Here, we see how the episodes with the
same DBC code are distributed over different clinical
pathways. If a DBC code is distributed over many clinical
Table 6 Number of clinical pathways that were found for each specialty
Medical speciality # DBC’s in
GDWH
# of clinical
pathways
Average CV
clinical pathways
# Clinical pathways
representing 95% of the data
Eye surgery 1,43,042 44 0.36 5
Dermatology 64,381 63 0.45 14
Internal medicine 1,10,752 73 0.56 16
Gastro enterology 26,596 85 0.54 26
Head and neck surgery 61,972 111 0.46 13
Cardiology 53,819 90 0.43 19
Rheumatology 20,894 49 0.41 8
Rehabilitation 10,023 49 0.42 18
General surgery 191,618 82 0.45 19
Neurology 80,960 38 0.53 9
Clinical geriatrics 2,048 20 0.43 8
Plastic surgery 13,059 46 0.41 8
Orthopaedic surgery 90,109 77 0.41 16
Urology 39,727 65 0.43 15
Gynaecology 82,773 121 0.43 25
Neurosurgery 5,775 29 0.38 7
Anaesthesiology 33,646 100 0.48 12
Paediatrics 37,633 58 0.44 14
Pneumonology 45,706 86 0.47 18
Sum 11,14,533 1,286 270
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Fig. 9 Distribution of DBCs over clinical pathways (named care
paths in this ﬁgure). Example for 4 DBC codes (labelled DBC 1 to
DBC 4). The grey value in each block reﬂects the percentage of DBCs
with code x that are also in clinical pathway y. For example, 100% of
the DBCs that have been registered under code DBC 1 are also in
clinical pathway 74. DBC code 2 is distributed 50-50% over clinical
pathways 74 and 341. The index of each clinical pathway corresponds
to average costs of the DBCs in the path
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123pathways, such as DBC code 3 in the example, then the
DBC code represents an inhomogeneous set of DBCs. By
representing the relation between DBC codes and clinical
pathways as in Fig. 9, we have a useful tool to increase the
cost homogeneity of the DBC codes and to cluster DBCs in
a small number of product groups.
The cost homogeneity of DBC codes is increased by
reﬁning thetreatmenttypecomponentofthe code sothatthe
relation betweenDBC codes and clinical pathways becomes
less fuzzy (e.g., DBC3 in Fig. 9). As an example, the former
treatment component in the DBC codes of General Surgery
speciﬁes whether the treatment is conservative (without
surgery) or with surgery. The most important reﬁnement is
that we include the setting of the treatment, i.e., whether the
surgery was in ambulatory care, day care, or clinical care. In
General Surgery, this reﬁnement decreased the average cost
inhomogeneity (=standard deviation/mean) of the DBCs
from 1.05 to 0.53! A similar reduction of the cost inhomo-
geneity with a factor 2 has also been established for other
medical specialties.
11
The task of reﬁning the DBC code is done with great
care. On the one hand, we have the inhomogeneity problem
caused by the fact that some DBC codes are not speciﬁc
enough, and on the other hand, there is a danger in making
the DBC codes too speciﬁc. Both situations could lead to
unwanted incentives like cherry picking, i.e., refusing to
help patients who are expected to generate more costs than
the reference price, and up-coding, i.e., if it is not clear to
which product a care episode should be assigned, it is
tempting to choose the most expensive one.
In this section, we have explained the method by which
new treatment codes are introduced which maximally
improve the mapping between DBC codes and clinical
pathways. The result of this procedure is given in Table 7.
The average CV is reduced with almost a factor 2. Most
effect was scored by separating surgical and conservative
treatments and separating clinical care, day care and out-
patient care. Also, introducing separate codes for expensive
prosthesis had a large effect, especially in orthopaedic
surgery. Another improvement is owed to cleaning up
inconsistencies between DBC codes and activity proﬁles.
For example, if the doctor used a treatment code indicating
surgery and no surgical procedure was in fact registered in
Table 7 Effect of reﬁning the treatment codes on the average cost homogeneity
Medical
specialty
# DBC’s
in GDWH
** CV before
conversion of
treatment type
** CV after
conversion
of treatment
CV before
conversion of
treatment
type (outliers
excluded)
CV after
conversion of
treatment type
(outliers
excluded)
# of DBC’s after
conversion of treatment
excl. Codes with less
than 5 observations
and invalid codes
# DBC codes
after conversion
of treatment type
Eye surgery 1,43,042 1.11 0.62 0.92 0.61 1,32,754 281
Dermatology 64,381 1.38 0.85 1.29 0.75 54,251 143
Internal medicine 1,10,752 3.28 1.45 1.83 0.80 91,856 682
Gastro enterology 26,596 1.45 0.62 1.55 0.72 11,291 262
Head and neck surgery 61,972 1.04 0.67 0.91 0.64 58,285 169
Cardiology 53,819 2.55 1.07 2.53 0.81 49,224 140
Rheumatology 20,894 1.64 0.80 1.25 0.78 19,515 133
Rehabilitation 10,023 1.00 1.14 0.74 0.82 7,912 239
General surgery 1,91,618 1.42 0.65 0.88 0.55 1,58,255 686
Neurology 80,960 2.30 0.87 2.06 0.85 75,992 458
Clinical geriatrics 2,048 1.87 0.76 0.67 0.67 1,319 64
Plastic surgery 13,059 1.07 0.61 0.67 0.48 11,218 194
Orthopaedic surgery 90,109 1.87 0.73 1.32 0.71 73,419 506
Urology 39,727 1.19 0.69 0.61 0.53 32,166 516
Gynaecology 82,773 1.62 0.73 1.21 0.63 68,129 155
Neurosurgery 5,775 1.91 0.66 0.81 0.57 4,770 54
Anaesthesiology 33,646 0.96 0.86 0.95 0.68 3,006 76
Paediatrics 37,633 1.63 0.83 1.31 0.73 24,390 600
Pneumonology 45,706 2.49 0.92 1.16 0.77 38,133 150
Sum/average 1,114,533 1.74 0.82 1.27 0.68 9,15,885 5,508
Outliers were deﬁned as those data points in the tails of the distribution which together form maximally 3% of the total volume in the distribution
and maximally affect the CV of the distribution
11 Note that the example treatment codes presented at the start of the
paper in Table 1 are those after the reﬁnement step.
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123the DBC proﬁle, then the treatment code was replaced with
a conservative treatment code, indicating the DBC was
performed without surgery. The total number of distinct
codes remained roughly the same: it reduced from 6,422 to
6,334 codes (excluding codes with less than 5
observations).
Step 3: Deﬁning product groups
As explained in Sect. 3.4, each patient episode of care (i.e.,
each DBC) has a DBC code and it can be attributed to a
clinical pathway. In other words, DBC codes and clinical
pathways are two alternative ways to group DBCs. Hence,
if we take a particular DBC code, we will see that the
DBCs with this code fall in different clinical pathways
(Table 8).
Now, the goal is to form sensible groups of DBC codes.
Here, the meaning of ‘sensible’ was deﬁned in Sect. 3.1.
For now, the most challenging criterion is that each group
should be homogeneous in terms of hospital resource uti-
lization. In other words, each episode in a group should
have undergone similar activities demanding similar
resources. If so, the episodes in a group will also be similar
in terms of costs.
In the methodology presented here, we operationalized
‘homogeneous in terms of hospital resource utilization’ as
‘homogeneous in terms of the underlying clinical path-
ways’. In other words, two DBC codes with episodes dis-
tributed in the same way of clinical pathways are
considered here to be very similar.
Technically, we are again dealing here with a clustering
problem. Now, we are not clustering episodes on basis of
their activities, but we are clustering DBC codes on basis
of their underlying clinical pathways. We again applied a
cluster algorithm
12 to automatically ﬁnd groups of DBC
codes with a similar distribution over clinical pathways
using a slightly altered similarity measure
13
Figure 10 shows the clustering result for all 650 DBC
codes for General Surgery. Each code was assigned a
‘DBC class index’ based on the clustering result. For
example from the ﬁgure, we can see that the DBC code
with index 500 has episodes in clinical pathways 2,894 and
1,281 (if we look carefully at the grey value, we see that it
has more episodes in pathway 1,281 since the link is almost
black which means close to 100%, whereas white means
0%). We also see that there are other DBC codes that also
link in the same manner with pathways 2,894 and 1,281.
These codes lie in the range of indices between 490 and
505.
The clinical pathways on the vertical axis are sorted in
terms of the average costs of the episodes in the pathways.
Hence, the most complex clinical pathway with index
11,511 is located on the bottom side of the ﬁgure. Actually,
the index is chosen to be a round-off of the average costs of
each episode in the pathway, which means that the average
cost of an episode in pathway 11,511 is approximately €
11.511.
The result shown in the ﬁgure is that 98% of all DBC
codes are clustered in 26 product groups. The remaining
2% consists of those (13) DBC codes that each form a
group by themselves (i.e., groups with one member).
Roughly, we see that episodes with the same DBC code are
distributed over 2–3 clinical pathways.
For General Surgery, the average CV of the individual
DBC codes is 0.53 and the group inhomogeneity is slightly
increased to 0.57. Hence, we reduced complexity from 650
DBC codes to 40 groups while only slightly increasing cost
inhomogeneity.Atthesametime,thegroupsareconstructed
such that they are maximally homogeneous in terms of the
underlying activity proﬁles of the care episodes.
Other examples of other specialties are Internal Medi-
cine with an average DBC code CV of 0.64 which
increases to an average group CV of 0.79, for Head and
Neck surgery we ﬁnd 0.61 and 0.67, respectively, and for
Rheumatology we ﬁnd 1.02 and 1.14. The Rheumatology
DBC codes are less homogeneous because of the vari-
ability in clinical stay. For Rheumatology this is hard to
avoid: by reﬁning the DBC coding schema, we introduce
the risk of creating unwanted incentives.
Manual reﬁnement by medical experts
The clustering of DBCs in groups (the statistical clusters)
as shown in Fig. 10 forms the basis of the product group
deﬁnition. As explained before, the groups were con-
structed such that they are homogeneous in terms of costs
and from the point of view of hospital resource utilization.
Still, there is number of additional factors that need to be
taken into account which cannot be tackled in an auto-
mated analysis process. These factors are as follows.
12 We used a variant of a hierarchical agglomerative clustering
algorithm, see for example Duda and Hart [17].
13 More precisely, the similarity between DBC codes is again
computed using the Jaccard measure. Now, the Jaccard measure is
used to compute the similarities between DBC codes based on their
distribution over clinical pathways. If we wish to compute the
similarity between two DBC codes by comparing their distributions
z and x over clinical pathways using the Jaccard measure we get
JW z ~; x ~ ðÞ ¼ z ~
TWx ~= z ~
TWx ~þ z ~  x ~ ðÞ
TWz ~  x ~ ðÞ

where the components
of the distribution vectors z ~ and x ~, for examplezi, represent the
frequency (a fraction between 0 and 1) with which the DBC code is
observed in clinical pathway i. The matrix W is used to account for
similarities in the clinical pathways themselvesWij ¼ v ~i   v ~jwhere v ~i is
the vector representing the average CTG activity proﬁle of a clinical
pathway, i.e., each component of v ~i corresponds to a CTG activity and
its value is equal to the average (normalized) costs of that activity in
pathway v.
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123• The workload of the medical specialist: In contrast to
the hospital activities, the workload of the medical
specialist has not been registered in the central data
warehouse. Instead, the specialists have determined a
reference workload for each DBC code by expert
opinion. In a separate statistical research project, these
times were validated and adjusted to real time mea-
surement data. With the validated doctor times, the
DBC groups form also the basis for the doctors’ fees.
• Political choices: some DBC codes were clustered in the
same group although they had different clinical path-
ways. For instance, the DBC codes with outpatient
surgery and day-care surgery were clustered in the same
product group. As a consequence, these groups are less
costhomogeneous butclustering theminthe samegroup
givesindividualhospitals anincentivetotreat patientsin
an outpatient setting instead of in day care.
The product groups were formed by experts from a
range of ﬁelds, i.e., the costing/accounting ﬁeld, the sta-
tistics ﬁeld and the medical ﬁeld. In this process, both the
DBC labels and the clusters were evaluated with external
parties (the scientiﬁc organisations) and proposals were
made to improve the DBCs and the clusters. In this process,
some special extra decisions had to be made. For example,
the decision to introduce an extra product for treatments
with expensive medicines or the decision to join two
clusters because the underlying DBC codes are medically
very similar while the clinical pathway distributions are not
too different.
As described in this paper, the product groups were
formed in such a way that the variability of costs and
reference workloads in a product group are not too large.
By consulting the scientiﬁc organizations of medical dis-
ciplines, the additional necessary medical expertise was
included. This ﬁnal step of reﬁning product groups based
on medical expertise was a manual step involving many
hours of analysing and discussing data and reﬁning the
groups by calculating the cost and workload homogeneity
of a product group. For a detailed example of clustering
DBCs, we refer to Duda and Hart [17].
A major problem was the inclusion of DBC codes that
were never observed in the data, although these codes
could in fact be registered in the future. As was mentioned
before, there were only statistical data for roughly 5% of all
theoretically possible DBC codes. Although this 5% (7,154
codes with at least 5 observations) is expected to account
for, say, more 95% of all care, the other unobserved codes
still need a place in the product structure. With the help of
medical experts, these DBC codes were attributed to either
existing product groups or to new theoretically constructed
product groups. For some medical specialties (radiother-
apy, clinical genetics, thorax surgery and hospital psychi-
atrics), there were no data available at all. By using other
data sources, for instance results from research projects,
and with the help of medical experts in these ﬁelds, product
groups were also formed for these specialties.
Result of step 3: Product groups
With the available data (7,154 DBC codes), 351 product
groups were formed. The average cost homogeneities,
expressed in CV, for most specialities are less than 1.00,
which is an internationally frequently observed value for
DRG groups. One must take into account that many of these
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Fig. 10 The result of clustering DBC codes. Each DBC code is
indexed with a ‘DBC class index’ and is placed next to the other
codes along the horizontal axis. The episodes associated with a DBC
code are distributed over clinical pathways indicated with grey values
(black means 100%, white means 0% of the episodes falls within the
pathway). DBC codes of which the episodes are distributed in the
same way over care paths (vertical axis) are placed in one group
(boundaries indicated with thin vertical lines). The clusters form the
basis of the DBC product groups
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123groups represent DBCs with a conservative outpatient
treatment (70% for some medical specialties). Because the
averagepriceofthesetreatmentsislow(forinstanceaverage
costs less than 200 euro’s), one activity more or less (for
instance a CT-scan) can contribute to a high CV value. The
more expensive clinical groups and outpatient groups with
treatments like operating procedures show a better result on
the CV. For ﬁnancing purposes, the cost-weighted average
CV is therefore a better measure to audit the results.
After also classifying the unobserved DBC codes, ﬁnally
687 groups were formed. These groups formed the base for
the introduction of DBCs in the reimbursement system of
Dutch hospitals and medical specialists in 2005.
The method in summary
Step number Detailed methodological choices
for version 1 of the DBC product
structure
0. Calculate cost prices of CTG
activities
In the ﬁrst version, this was done
by the taking the median of each
CTG code over the hospitals
1 a) Determine local clusters
within activity classes
In the ﬁrst version, local clusters
are fully determined by costs
only
1 b) Determine clinical pathways Use a decision tree algorithm to
determine the most relevant
sequences of activity classes
within each medical specialty
2. Determine relation between
clinical pathways and reﬁne the
treatment type
By using the conﬁdence intervals
of a binomial distribution,
statistically exceptional DBCs
were removed from the
mapping
3 a) Cluster DBC codes based on
similarity of the distribution of
individual DBCs over clinical
pathways
Use a hierarchical agglomerative
(bottom up) clustering
algorithm
Use Jaccard’s measure as a
similarity measure
The similarity between clinical
pathways is taken into account
in the similarity measure
3 b) Determine ﬁnal product
groups by manual reﬁnement by
medical experts
Discussion
The focus of this paper is on the mathematical and statis-
tical methodology but the relevance of the results is pri-
marily in the health economics area. First, the outcomes of
this study are used to introduce a new reimbursement
system for hospitals. Secondly, by specifying a number of
medical and cost relevant product groups, the result offers
opportunities to manage the hospital in a better way. Pre-
viously, hospital management did not have other instru-
ments in controlling costs than cost budgets for each
department. Now, the relation between production, costs
and income can be analysed and improved. By examining
clinical pathways, management and medical specialists
have information on resource utilization in relation to their
core production objects, i.e., DBCs. This can be compared
with a best practice or internal guidelines.
At the starting point of the new system, efﬁciency dif-
ferentials between hospitals might have differed signiﬁ-
cantly for different DBC codes and activities. Hence, for
some codes and activities, average costs might have
decreased heavily due to specialization, whereas for others
average costs might have increased. Exactly, this expected
effect was one of the reasons, according to the Ministry,
besides the creation of competition and the enhancement of
demand-driven care delivery, to implement the new case-
mix reimbursement system, though one must be more
precise by stating that this implementation has been only
partial. The A-segment of hospital care has still a budget
reimbursement. The B-segment is the competition segment
of hospital care where hospitals and insurers negotiate
about price, volume and quality of DBCs. This will have its
effect in reducing the length of stay (LOS), more outpatient
care and more day care. The over-reimbursement that has
been reported in the annual statements of the hospitals
during the years 2006 and 2007 [5] may be an indication of
this effect. The average difference for small hospitals is
larger than 5%. The average difference for large hospitals
is less than 5%. This might be explained from the negoti-
ations between hospitals and health insurers. As health
insurers become more experienced with the new system,
they will pay more attention to the way they accept or
reject bills. Their control system becomes better as they
become more experienced with the system. An interesting
phenomenon is the work in progress (WIP), which is
introduced with the new casemix reimbursement system.
The new system is an episode-based billing system. This
means that there is work in progress at the end of the ﬁscal
year, which must be valued. The euro equivalent of the
change in work in progress is described as income in the
annual statement. Annual statements show that the work in
progress had a substantial effect in 2006, which decreases
in 2007. This implies that the hospitals have become more
experienced with the system and succeed in closing epi-
sodes earlier, leading to better cash ﬂows.
Furthermore, it seems that there are large differences
within the same groups of similar hospitals. Apparently,
hospitals react differently to the change in funding. Some
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123are very eager in adjusting their administrative procedures;
others react more slowly, leading to cash ﬂow problems as
the liquidity position of most hospitals is not very well.
Another explanation can be found in casemix differences
between hospitals. Some hospitals are better prepared in
optimizing their casemix in order to optimize their cash
ﬂows within the new reimbursement system. This implies
sending the more severe patients to teaching or large non-
teaching hospitals and actively attracting elective patients
which can be treated efﬁciently. Though there are sub-
stantial differences in the average result between small and
large hospitals, the difference between the two groups is
not signiﬁcant. This may indicate that there is not much
differentiation between hospitals in functions and severity
of illness of patients, at least not so much as primarily
expected. Apparently, small hospitals also treat complex
patients and use innovative techniques, and also large
hospitals treat very many highly elective patients. The lack
of differentiation in functions between hospitals is some-
thing which has grown within the budget funding system,
but will gradually disappear as health insurers are able to
negotiate about individual casemix products and their
costs.
If the aim is to avoid future ﬁnancial risk for hospitals
when introducing casemix reimbursement, a number of
policy implications can be described. An important rec-
ommendation is that the system needs permanent
adjustment. This is done on a yearly basis by a national
organization. Another important public policy implication
is that the new system must always have a relation to the
old system. Otherwise, reallocation effects and unin-
tended over-payment can be expected. The relation
between the two reimbursement systems can be realized
by using a closing tariff that is used in the DBC casemix
system. If the revenues based on the new casemix
reimbursement system are higher than the former budget
of a speciﬁc hospital, the difference can be mitigated by
using a negative of positive percentage upon the DBC
prices in the next ﬁscal year. This option may enhance
the support for the implementation of the system.
Another important public policy implication is that a
casemix index has to be developed to compensate hos-
pitals for severity of illness, socio-economic characteris-
tics of the patients and teaching functions. A speciﬁc
casemix factor related to speciﬁc hospital functions is
better for reimbursement purposes than allowing the
billing of parallel DBCs that means a DBC for each
diagnosis of a speciﬁc patient. Future research must
deﬁne in more detail which part of the total ﬁnancial risk
is due to severity of illness, socio-economic characteris-
tics of the patients and teaching functions. Finally, a
policy implication is that maintenance of the uniform
national coding system for intermediate products remains
necessary in any form of casemix reimbursement, due to
rapid innovations in the medical ﬁeld. Since the DBC
casemix system relies on a bottom-up costing model
based on cost allocation to intermediate products, the
number and kinds of intermediate products represented in
the data set are essential for sound DBC prices.
Apart from the yearly adjustments in DBC tariffs for the
A-segment, a more fundamental change is being introduced
in the system. The DBC casemix system has brought about
much more insight in prices, content and quality of deliv-
ered care, both nationwide and within hospitals. Still areas
for improvement were identiﬁed by the various users of the
system. These include the complexity of the system
(30,000 DBCs in practice) and the classiﬁcation of diag-
noses which lacks uniformity. Also, the severity of care has
not been sufﬁciently included. The shortcomings were
addressed in close cooperation with those who use the
system in their daily practice: hospitals, physicians and
insurance companies. These problems made it necessary to
launch a project for improving the casemix system: DOT,
which is expected to be introduced in 2012. In DOT, the
myriad DBCs are replaced by only a few thousand care
products.
An interesting point to reﬂect upon is whether the
technical methodology presented in this paper would still
make sense with hindsight. The methodology was devel-
oped taking the DBC and the CTG activity coding systems
introduced in the years 2002–2004 as a given fact. In
addition, policy decided to work with DBC codes and with
product groups. Even with hindsight, we believe that the
methodology presented here is optimal for the conditions
and policies at that time.
The areas for improvement mentioned above required
fundamental changes in the underlying coding systems.
Indeed, the necessary steps taken in the development of the
new DOT system are as follows. First, adopt the ICD10
system with all its hierarchical richness to code diagnoses.
Secondly, reﬁne the coding system of medical activities to
better relate to current medical practice. Thirdly, eliminate
the treatment code and replace it with a system which
automatically extracts the relevant attributes from the
registered activity proﬁle. By using the hierarchical ICD10
system, it is now possible in DOT to form groups of epi-
sodes which are similar not only in terms of their activity
patterns but which are also similar in terms of their medical
diagnosis. Many of the ideas and techniques presented here
were again applied to deﬁne the new DOT products. In
particular, the decision tree algorithm (up to the details of
the Matlab programming code) to deﬁne care paths pre-
sented in Sect. 3.3.2 was used in DOT to directly deﬁne
DOT products (without the intermediate care path deﬁni-
tion step). Also, the clustering algorithm was used to
identify new activity classes.
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